Imaging and biodistribution of Her2/neu expression in non-small cell lung cancer xenografts with 64Cu-labeled trastuzumab PET

被引:42
作者
Paudyal, Pramila [1 ,2 ]
Paudyal, Bishnuhari [1 ,2 ]
Hanaoka, Hirofumi
Oriuchi, Noboru [1 ,2 ]
Iida, Yashuhiko
Yoshioka, Hiroki [1 ,2 ]
Tominaga, Hideyuki [1 ,2 ]
Watanabe, Satoshi [3 ]
Watanabe, Shigeki [3 ]
Ishioka, Noriko S. [3 ]
Endo, Keigo [1 ,2 ]
机构
[1] Gunma Univ, Grad Sch Med, Dept Diagnost Radiol, Maebashi, Gunma, Japan
[2] Gunma Univ, Grad Sch Med, Dept Nucl Med, Maebashi, Gunma, Japan
[3] Japan Atom Energy Agcy, Quantum Beam Sci Directorate, Takasaki, Gunma, Japan
关键词
PHASE-II TRIAL; BREAST-CANCER; ANTIBODY; GEMCITABINE; CISPLATIN; MICE;
D O I
10.1111/j.1349-7006.2010.01480.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Non-small cell lung carcinomas (NSCLC) overexpress the Her2/neu gene in approximately 59% of cases. Trastuzumab, a humanized monoclonal antibody, interferes with Her2 signaling and is approved for the treatment of Her2/neu overexpressing breast cancer. However, its therapeutic use in Her2/neu overexpressing NSCLC remains obscure. The present study aimed to determine the role of 64 Cu-labeled trastuzumab positron emission tomography (PET) for non-invasive imaging of Her2/neu expression in NSCLC. Trastuzumab was conjugated with the bifunctional chelator 1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid (DOTA) and radiolabeled with Cu-64. The molecular specificity of DOTA-trastuzumab was determined in NSCLC cell lines with Her2/neu overexpression (NCI-H2170) and negative expression (NCI-H520). Imaging of Her2/neu expression was performed in NCI-H2170 tumor-bearing mice with 64 Cu-DOTA-trastuzumab PET and 64 Cu-DOTA-IgG. In vitro studies revealed specific binding of DOTA-trastuzumab in the Her2/neu positive NCI-H2170 cells, while no binding was seen in the Her2/neu negative NCI-H520 cell line. Biodistribution and PET studies revealed a significantly high accumulation of 64 CuDOTA-trastuzumab in the Her2/neu overexpressing NCI-H2170 tumor at 24 and 48 h post-injection (21.4 +/- 1.4% and 23.2 +/- 5.1% injection dose/gram (% ID/g), respectively). PET imaging of Her2/neu negative NCI-H520 tumors showed much less uptake of 64 CuDOTA- trastuzumab (4.0% ID/g). The NCI-H2170 tumor uptake of 64 Cu-DOTA-trastuzumab was significantly higher than that of 64 Cu-DOTA-IgG (P < 0.0001). 64 Cu-DOTA-trastuzumab showed a very clear image of a Her2/neu positive tumor and appeared to be effective as a PET tracer for imaging of Her2/neu gene expression in NSCLC, suggesting its potential clinical use for identifying patients that might benefit from trastuzumab-based therapy. (Cancer Sci 2010; 101: 1045-1050)
引用
收藏
页码:1045 / 1050
页数:6
相关论文
共 35 条
  • [1] ANDERSON CJ, 1992, J NUCL MED, V33, P1685
  • [2] Lymph node involvement, recurrence, and prognosis in resected small, peripheral, non-small-cell lung carcinomas: Are these carcinomas candidates for video-assisted lobectomy?
    Asamura, H
    Nakayama, H
    Kondo, H
    Tsuchiya, R
    Shimosato, Y
    Naruke, T
    [J]. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1996, 111 (06) : 1125 - 1134
  • [3] Baselga J, 1998, CANCER RES, V58, P2825
  • [4] Behr TM, 2001, NEW ENGL J MED, V345, P995
  • [5] Bunn PA, 2001, CLIN CANCER RES, V7, P3239
  • [6] Cai WB, 2006, J NUCL MED, V47, P2048
  • [7] Correlating EGFR expression with receptor-binding properties and internalization of 64Cu-DOTA-cetuximab in 5 cervical cancer cell lines
    Eiblmaier, Martin
    Meyer, Laura A.
    Watson, Mark A.
    Fracassol, Paula M.
    Pike, Linda J.
    Andersonl, Carolyn J.
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2008, 49 (09) : 1472 - 1479
  • [8] The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors
    Garrett, TPJ
    McKern, NM
    Lou, MZ
    Elleman, TC
    Adams, TE
    Lovrecz, GO
    Kofler, M
    Jorissen, RN
    Nice, EC
    Burgess, AW
    Ward, CW
    [J]. MOLECULAR CELL, 2003, 11 (02) : 495 - 505
  • [9] Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer
    Gatzemeier, U
    Groth, G
    Butts, C
    Van Zandwijk, N
    Shepherd, F
    Ardizzoni, A
    Barton, C
    Ghahramani, P
    Hirsh, V
    [J]. ANNALS OF ONCOLOGY, 2004, 15 (01) : 19 - 27
  • [10] Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas
    Hirsch, FR
    Varella-Garcia, M
    Franklin, WA
    Veve, R
    Chen, L
    Helfrich, B
    Zeng, C
    Baron, A
    Bunn, PA
    [J]. BRITISH JOURNAL OF CANCER, 2002, 86 (09) : 1449 - 1456